Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Metastatic HR+/HER2− Breast Cancer Market Expected To Become By 2029 Compared With Its 2025 Level?
The metastatic hr+/her2− breast cancer market has experienced robust growth in its size over recent years. It is anticipated to increase from $9.91 billion in 2024 to $10.89 billion in 2025, registering a compound annual growth rate (CAGR) of 10.0%. Historically, this market expansion can be linked to factors such as increasing awareness concerning early diagnosis, a rise in diagnosis rates, positive outcomes from clinical trials, substantial pharmaceutical investments, and the growing integration of combination therapies.
The market for metastatic hr+/her2− breast cancer is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a valuation of $15.79 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth during the forecast timeframe include the wider uptake of innovative treatments, the rising application of immunotherapy, market penetration into new regions, initiatives from patient advocacy and support groups, and an increased emphasis on enhancing patients’ quality of life. Key developments expected within this period encompass next-generation sequencing (NGS), progress in liquid biopsy techniques, identification of new biomarkers, advancements in cell and gene therapy, and the continued development of monoclonal antibodies (mAbs).
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21220&type=smp
Which Drivers Are Shaping The Metastatic HR+/HER2− Breast Cancer Industry’s Market Share?
The escalating use of hormone replacement therapy (HRT) is anticipated to drive the expansion of the metastatic HR+/HER2− breast cancer market in the foreseeable future. This therapy constitutes a medical intervention aimed at supplementing or substituting hormones present at reduced concentrations within the body, primarily administered during menopause or to address hormonal deficiencies. The rising adoption of HRT stems from its proven efficacy in enhancing treatment results, its fewer adverse effects compared to conventional treatments, and ongoing progress in precision medicine. HRT proves beneficial for metastatic HR+/HER2− breast cancer patients by mitigating estrogen deficiency symptoms linked with menopause, including hot flashes and vaginal dryness. It achieves this without impeding the efficacy of endocrine therapies, as its primary action addresses hormonal imbalances rather than directly targeting cancerous cells, thereby contributing to an improved quality of life for individuals undergoing cancer treatment. As an illustration, figures from NHS England, a UK-based government agency, indicated that in October 2023, a total of 11 million hormone replacement therapy (HRT) items were prescribed in England during 2022-23, representing a significant 47% surge from the 2021-22 period. Consequently, the growing utilization of hormone replacement therapy (HRT) is a significant catalyst for the metastatic HR+/HER2− breast cancer market.
What Are The Segment Types Shaping The Metastatic HR+/HER2− Breast Cancer Market?
The metastatic hr+/her2- breast cancermarket covered in this report is segmented –
1) By Drugs: Paclitaxel; Tamoxifen; Vinblastine; Raloxifene; Docetaxel; Other Drugs
2) By Treatment: Radiation Therapy; Vitamin Therapy; Macrobiotic Diets; Homeopathy; Herbal Medication
3) By End-User: Hospitals; Clinics; Other End-User
Subsegments:
1) By Paclitaxel: Generic Paclitaxel; Taxol
2) By Tamoxifen: Generic Tamoxifen; Nolvadex
3) By Vinblastine: Generic Vinblastine; Velban
4) By Raloxifene: Generic Raloxifene; Evista
5) By Docetaxel: Generic Docetaxel; Taxotere
6) By Other Drugs: Letrozole; Anastrozole; Exemestane; Palbociclib; Ribociclib; Abemaciclib
What Key Innovation Trends Are Fueling Advancements In The Metastatic HR+/HER2− Breast Cancer Market?
Major companies operating in the metastatic HR+/HER2− breast cancer market are focusing their efforts on developing combination therapy to expand their indications, market reach, and available treatment options. Combination therapy refers to a treatment strategy that utilizes the simultaneous application of two or more therapeutic agents, potentially including chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other approaches, to more effectively manage a medical condition. This approach works by targeting various pathways, enhancing the overall treatment response, and decreasing the chance of conditions, such as cancer, developing resistance to any single treatment. As an illustration, in July 2023, Merck & Co., Inc., a pharmaceutical company based in the US, announced the outcomes of its Phase 3 KEYNOTE-756 trial. This study investigated KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, when combined with chemotherapy that has received approval from the Food and Drug Administration, a US government body. The trial successfully met its primary endpoint by demonstrating a notable improvement in the pathological complete response (pCR) rate among patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 stands as the first positive Phase 3 trial to show a statistically significant enhancement in pCR rate with an immunotherapy regimen in the neoadjuvant setting for this patient population. The trial’s design involved assessing KEYTRUDA alongside chemotherapy as a neoadjuvant treatment, followed by adjuvant KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.
Who Are The Primary Competitors In The Global Metastatic HR+/HER2− Breast Cancer Market?
Major companies operating in the metastatic HR+/HER2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Metastatic HR+/HER2− Breast Cancer Market During The Forecast Period?
North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic HR+/HER2- breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Metastatic HR+/HER2− Breast Cancer Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21220&type=smp
Browse Through More Reports Similar to the Global Metastatic HR+/HER2− Breast Cancer Market 2025, By The Business Research Company
Breast Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
Breast Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Breast Imaging Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/breast-imaging-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model